Skip to Main Content

Advertisement

Skip Nav Destination

Current Issue

February 2024

When the Hoofbeats Are From Zebras

Diagnosing rare diseases requires physicians to think broadly, collaborate with specialists, and be persistent.


 

Viewpoints

Editor’s Corner

Metrics by Which We Measure Quality: From Questions to Psychological Safety

Notes from the Hill

Navigating the Intersection of Medicine and Policy: A Purpose-Driven Journey of Impact

A Day in the Life

Leading Breakthroughs in Blood Cancer Care: E. Anders “Andy” Kolb, MD

From the Desk Of... Videos

From the Desk Of... February 2024 

Education

You Make the Call

You Make the Call: Would you proceed with a 7/8 matched unrelated donor alloHCT in a patient with severe acquired aplastic anemia?

You Make the Call Readers' Response

Would you proceed with a 7/8 matched unrelated donor alloHCT in a patient with severe acquired aplastic anemia?

Algorithms in Hematology

How I Treat Erythropoietic Protoporphyria and X-Linked Protoporphyria

Spotlight

Feature Articles

When the Hoofbeats Are From Zebras

Blood Beyond Borders

Trials and Tribulations: Running Clinical Trials in LMICs Can Be a Challenge

Drawing First Blood

Should Iron Deficiency Be Treated With Oral or IV Iron?

News

Written in Blood

Inotuzumab as a Bridging Therapy to Eradicate MRD Improves OS in Patients With ALL
Time-Limited Ibrutinib, CD19-Directed CAR-T Combo Shows Efficacy for Poor-Risk, R/R Mantle Cell Lymphoma
Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Blood Advances in a Different Vein

Study Examines Quality and Potential Use of Real-World Data in DLBCL
Study Identifies Drugs With Greatest Association With Drug-Induced Hemolytic Anemia

Literature Scan

Etranacogene Dezaparvovec Bests Extended Half-Life Factor IX Products in Hemophilia B Prophylaxis
Study Proposes Recommendations for Infections During Teclistamab Treatment of R/R MM
IKZF1 Alterations an Independent Marker of AML Risk

Latest and Greatest

FDA Approves R/R MDS Treatment
Bayer Withdraws New Drug Application for FL Treatment
cTTP ERT Receives FDA Approval
FDA Approves Two Cell-Based SCD Gene Therapies

ASH Directions

The ASH Guide to Advocacy: How to Make an Impact in Hematology

Data Stream

February 2024 Data Stream

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement